Coherus BioSciences Inc (NASDAQ: CHRS) stock closed at $11.83 on 8/5/22 after a major increase of 11.8%. Moreover, unusually high trading volume at 160% of normal accompanied the advance. The stock has risen 40.2% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, CHRS is expected to be a modest Value Eraser.
Coherus BioSciences has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Coherus BioSciences has a very low Power Rating of 6 and a very low Appreciation Score of 5, resulting in the Lowest Value Trend Rating.
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.